CollPlant Biotechnologies Ltd. (CLGN)
Automate Your Wheel Strategy on CLGN
With Tiblio's Option Bot, you can configure your own wheel strategy including CLGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLGN
- Rev/Share 0.045
- Book/Share 1.1755
- PB 1.7439
- Debt/Equity 0.2288
- CurrentRatio 4.4377
- ROIC -1.0426
- MktCap 23481725.0
- FreeCF/Share -1.2725
- PFCF -1.611
- PE -1.4138
- Debt/Assets 0.1647
- DivYield 0
- ROE -0.8793
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
CollPlant Biotechnologies Ltd. (CLGN) Q4 2024 Earnings Call Transcript
Published: March 26, 2025 by: Seeking Alpha
Sentiment: Neutral
CollPlant Biotechnologies Ltd. (NASDAQ:CLGN ) Q4 2024 Earnings Conference Call March 26, 2025 10:00 AM ET Company Participants Dory Kurowski - LifeSci Advisors Yehiel Tal - CEO Eran Rotem - Deputy CEO and CFO Conference Call Participants Swayampakula Ramakanth - H.C.
Read More
COLLPLANT BIOTECHNOLOGIES REPORTS 2024 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
CollPlant announces six-month study data from its regenerative breast implant program, which could provide a revolutionary alternative to women for aesthetic or medical purposes and aims to address a $3 billion market opportunity Recently received a $2 million development payment from AbbVie Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel , March 26, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced its 2024 financial results and provided a corporate update.
Read More
CollPlant Expands Distribution for its VergenixSTR Product in Europe and Asia
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
REHOVOT, Israel , Feb. 24, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or "CollPlant", a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced the expansion of its distribution channels for its Vergenix™ STR product, in Europe and Asia. VergenixSTR is based on the Company's rhCollagen technology and is intended for the treatment of tendinopathy by promoting healing and repair of tendon injuries in a variety of tendons including the elbow tendon (for treatment of "tennis elbow"), rotator cuffs, patellar tendons, the Achilles tendon, and hand …
Read More
CollPlant Biotechnologies Provides a Corporate Update
Published: February 12, 2025 by: PRNewsWire
Sentiment: Neutral
- Additional patent granted for photocurable dermal filler- Update on AbbVie dermal filler program and achievement of contingent payment- Plan for cost reductions in place to extend cash runway REHOVOT, Israel , Feb. 12, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today provided a corporate update. Photocurable Dermal Filler Program: Additional Patent Granted CollPlant today announced it has been granted U.S. Patent No.
Read More
About CollPlant Biotechnologies Ltd. (CLGN)
- IPO Date 2018-01-31
- Website https://www.collplant.com
- Industry Biotechnology
- CEO Mr. Yehiel Tal
- Employees 57